BioSpace News Archive

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product.

Geron Corporation (Nasdaq: GERN), today announced the completion of patient enrollment in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS).

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), announced today the enrollment of the first patient in the US in its Phase IIb clinical trial with vafidemstat, a selective inhibitor of the epigenetic target LSD1, in Borderline Personality Disorder (BPD) patients.

Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced planned enrollment of the PEERLESS trial.

I-Mab (the “Company”) (Nasdaq: IMAB), today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the IND submission for the initiation of phase 2 clinical trial of efineptakin alfa (also known as TJ107/GX-I7/NT-I7) in combination with PD-1 antibody in patients with advanced solid tumors.

Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that vadadustat efficacy and safety data related to clinical outcomes among patients with anemia due to chronic kidney disease (CKD) will be presented at the American Society of Nephrology Kidney Week 2021 (ASN Kidney Week).

Geneoscopy Inc., a life sciences company focused on the development of diagnostic tests for gastrointestinal health, announced it has named Haytham Gareer, MD, Ph.D. to serve as the company’s Chief Medical Officer.

Lineage Cell Therapeutics, Inc. today announced that Lineage will be featured in the B. Riley Securities Fall 2021 “Growth Biotech Best Idea” Virtual Series

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that two abstracts were accepted for presentation at the virtual 2021 American Society of Nephrology (ASN) Annual Meeting to be held November 4-7, 2021.

Athenex (NASDAQ: ATNX), the leading developer of NKT cell therapy and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital today announced that the U.S. Patent and Trademark Office has allowed patent claims around its NKT cellular immunotherapy platform.